Search the Newsreel

Boston Scientific Corp. stock underperforms Tuesday when compared to competitors

Boston Scientific Corp. (BSX) shares fell by 1.87% on Tuesday, closing at $50.47, underperforming its competitors and the broader market. This decline occurred during a generally down trading session, with the S&P 500 Index falling 0.69% and the Dow Jones Industrial Average dropping 0.22%. …

Pulse (PLSE) Earnings Review: EPS Exceeds Its Estimate in the Current Update; Reaction Snapshot

Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains

Gilead Sciences Inc. (GILD) stock saw a daily gain of 3.25% on Tuesday, closing at $143.44. Despite this increase, the stock underperformed compared to broader market indices, with the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) also experiencing declines. This marked …

Boston Scientific stock holds in the low $51 range as Q2 2026 margins and EPS beat guidance

Boston Scientific's stock is trading in the low $51 range despite the company reporting stronger-than-expected Q2 2026 results, including increased margins and adjusted EPS that surpassed guidance. The medical device group saw its stock decline by 46% from the start of 2026, leading to …

Jupiter (JUNS) Quarterly Figures: EPS Lands Above Forecast in the Latest Session; Post-Report Move: Shares Finish 3.67% Down in the Current Update - Debt Analysis Report

Eurofins Scientific SE: Weekly Report on Share Repurchases from 10th August to 14th August 2026

LUXEMBOURG, August 18, 2026--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC …

Anavex (AVXL) Q2 2026 Results: EPS Prints Above Forecast in Latest Trading; Reaction Snapshot: Shares Finish 3.27% Down - Revenue Warning Signal

Jupiter (JUNS) Quarterly Figures: EPS Lands Above Forecast in the Latest Session; Post-Report Move: Shares Finish 3.67% Down in the Current Update - Pre-Earnings Setup

Anixa (ANIX) Latest Results Brief: EPS Prints Above Forecast at the Close; Post-Earnings Trading: Shares Finish 3.30% Lower in the Latest Reading - EBITDA Analysis

Burcon NutraScience Stock Falls 7.50%: Is TSX:BU Facing a Commercialization Reality Check?

Twist Bioscience (NASDAQ: TWST) insider plans multimillion-dollar stock sale

An officer at Twist Bioscience (TWST), Patrick Finn, has filed a Rule 144 notice to sell up to 78,355 shares of common stock through Fidelity Brokerage Services LLC, valued at approximately $9.5 million. These shares were primarily acquired through restricted stock vesting and a …

Boston Scientific Stimulator Lawsuit Alleges Spine Implant Caused Nerve Damage, Shocks

A Kentucky man has filed a product liability lawsuit against Boston Scientific, alleging that its spinal cord stimulator caused unexpected electric shocks and permanent nerve damage, despite being marketed for chronic pain relief. The lawsuit claims Boston Scientific knew about the device's "unacceptably high …

Why Satellos Bioscience Inc. stock is gaining today

Castle Biosciences (CSTL) Edges Lower to $29.66: Diagnostic Stock Holds Key Support Zone - Profitability Factor

TD Cowen Lowers Ciena (NYSE:CIEN) Price Target to $575.00

TD Cowen has reduced its price target for Ciena (NYSE:CIEN) to $575.00 from $675.00, while maintaining a "buy" rating, indicating a potential 40% upside. This adjustment comes despite Ciena reporting strong quarterly earnings and revenue that surpassed analyst expectations, with revenue increasing 39.5% year-over-year. …

Why COSCIENS Biopharma Inc. stock is plummeting today

Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript

Harvard Bioscience (HBIO) reported an 11% revenue growth in Q2 2026, driven by strong demand from CRO customers and new product platforms, leading to a raised full-year revenue guidance to 3-5%. Despite top-line success, a product and geographic mix shift towards lower-margin segments, including …

HURA: All proposals passed, including director elections and share issuance, with no stockholder questions

TuHURA Biosciences, Inc. (HURA) held its AGM 2026 where all proposals were passed, including director elections, share issuance, executive compensation, and auditor ratification. Stockholders supported the board's recommendation for a three-year frequency for compensation votes, and no questions were raised during the meeting. This …

Alivus Life Sciences acquires 76% stake in IQGenX Pharma for ₹9.12 crore

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Anixa Biosciences announced that its management, led by Chairman and CEO Dr. Amit Kumar, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will highlight progress in their ovarian cancer CAR-T therapy, lira-cel, which has advanced to its highest dose …

Anixa to present cancer data: longest survival is about 28 months

Anixa Biosciences will present clinical progress on its breast cancer vaccine and ovarian cancer CAR-T therapy, lira-cel, at the H.C. Wainwright 28th Annual Global Investment Conference. The breast cancer vaccine completed a Phase 1 trial with 74% immune response, and preparations for Phase 2 …

Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative?

Harmony Biosciences (HRMY) reported strong Q2 2026 earnings, with net income of US$75.43 million and diluted EPS of US$1.28, and completed a US$50 million share repurchase program. While these results reinforce the company's profitability, the core investment narrative remains largely unchanged, with a continued …

Why Burcon NutraScience Corporation stock plummeted yesterday

Die Gilead-Sciences-Aktie legt nach starkem Quartal und solider Nachfrage leicht zu

IDEAYA Biosciences (IDYA) Reports Second Quarter Results, Is The Valuation Still Justified?

IDEAYA Biosciences (IDYA) recently reported Q2 2026 results with $8.86 million in revenue and a net loss of $112.45 million, leading investors to re-evaluate the stock despite a strong 12-month performance. The company's current Price-to-Sales (P/S) ratio of 15.1x is considered expensive compared to …

Pulse Biosciences (PLSE) Grants Equity Awards to New Hires Amid High Price-to-Sales Valuation

Pulse Biosciences (PLSE) has granted equity awards to five new hires, totaling options for 16,950 shares, to attract talent crucial for advancing its medical device technologies. The company exhibits an extremely high Price-to-Sales ratio of 2755.9x, indicating strong market expectations despite its unprofitable and …

Supriya Lifescience Q1 Results: Revenue up 31% YoY, EBITDA falls 8%

Suven Life Sciences Limited Rights 2022-10.11.22 For Shares Revenue Breakdown – BSE:SUVEN_RE

SinoMab BioScience COO and Executive Director Steps Down

Boston Scientific: CEO kauft 186.240 Aktien

H.C. Wainwright reiterates Assembly Biosciences stock rating at buy

H.C. Wainwright has reiterated a Buy rating and a $50.00 price target for Assembly Biosciences (NASDAQ:ASMB), aligning with a broader analyst consensus of a Strong Buy. The company recently reported Q2 2026 results and is expanding the clinical development of its drug ABI-6250, with …

Ensysce Biosciences director Gower buys $444,169 in company stock

Ensysce Biosciences director Bob G. Gower recently purchased $444,169 worth of company stock through open market transactions, increasing his direct holdings to 916,740 shares. These purchases occurred between April and August 2026, with share prices between $0.484 and $0.495, while the stock currently trades …

Meeder Asset Management Inc. Invests $17.12 Million in Gilead Sciences, Inc. $GILD

Meeder Asset Management Inc. has acquired 135,547 shares of Gilead Sciences, Inc. (NASDAQ:GILD) valued at approximately $17.12 million, making it the firm's 25th-largest holding. Institutional investors collectively own 83.67% of the company, which recently reported strong quarterly revenues of $7.80 billion and declared a …

1,205,587 Shares in USANA Health Sciences, Inc. $USNA Bought by Pzena Investment Management LLC

Pzena Investment Management LLC has acquired 1.21 million shares of USANA Health Sciences (NYSE:USNA) worth approximately $25.7 million, establishing a 6.53% stake in the company. This comes as USANA Health Sciences faces negative analyst sentiment, including "Sell" ratings, recent downgrades, and insider selling activity …

Science Applications International (SAIC) Could Be 8% Overvalued As $400 Million Contract Adds Momentum

Science Applications International (SAIC) recently secured a $400 million contract, bringing its Intel Space awards to over $1.6 billion. Despite this momentum and recent share price gains, analysts believe the stock is approximately 7.5% overvalued, with a fair value of $117.80 compared to its …

Ensysce Biosciences Insider Bought Shares Worth $444,169, According to a Recent SEC Filing

An insider at Ensysce Biosciences, Inc. (ENSC) recently purchased shares valued at $444,169, as reported in a new SEC filing. The company, a clinical-stage pharmaceutical firm, specializes in developing solutions for severe pain relief with a focus on reducing opioid misuse, abuse, and overdose. …